Transaction · 0001652410-26-000002

Hecht Beth

Hecht Beth, SR, reported an open-market or private sale at Xeris Biopharma Holdings, Inc. involving 16667.000000 shares for an estimated $123775.81. Reported holdings after the transaction were 1308103.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SSR
XERSXeris Biopharma Holdings, Inc.
Filing timeJan 05
Trade dateJan 02, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$7.35
Pre-filing
1mo ago -5.3%1w ago -5.3%1d ago -5.3%
Returns since
7d +0.0%30d +0.1%90d -17.8%180d +12.5%1y +15.4%

XERS price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
XERS since 2026-01-05Filed 241 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001652410-26-000002
Common Stock
Transaction date
Jan 02, 2026
Filed Jan 05, 2026, 11:01 PM · 3d delay
Shares
16.6k sh
$743 per share
Estimated value
-$12.3M
Computed from shares × price
Holdings after
1.30M sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

See Remarks

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

  2. F2

    The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.280 to $7.740, inclusive. The reporting person undertakes to provide to the Is…

  3. F3

    Includes 2,627 shares acquired on June 30, 2025 and 1,967 shares acquired on December 31, 2025 under the issuer's 2018 Employee Stock Purchase Plan, as amended.

Original filing · 0001652410-26-000002
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

XERS